AB0633 Treating to target ultrasound findings only is equivalent to urate-lowering therapy in patients with chronic gout.
Identifieur interne : 000169 ( Main/Exploration ); précédent : 000168; suivant : 000170AB0633 Treating to target ultrasound findings only is equivalent to urate-lowering therapy in patients with chronic gout.
Auteurs : K. Kume ; K. Amano ; S. Yamada ; T. Kanazawa ; H. Ohta ; K. Hatta ; H. Komori [Japon]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Background Urate-lowering therapy (uric acid<6.0 mg/dL) (ULT) is recommended in chronic gout. In these days ultrasound (US) is very improved, and useful for diagnosis and treatment. Objectives To comparerecurrent gout attacks in chronic gout treated by US findings normalization strategy or ULT strategy. Methods We designed an open label, randomized controlled trial. We screened 74 chronic gout (uric acid>7.0 mg /ld., and double contour sign of US findings in any joint) for inclusion. 63 gout patients were randomly allocated either US strategy group (US group) or ULT group(C group). In both strategies febuxostat is used. US strategy is performed US by 4 weeks. Double contour sign or urate crystals were evaluated; febuxostat is intensified to dissolve it. ULT strategy is performed blood examination by 4 weeks. Febuxostat is intensified to target uric acid <6.0mg/dL. Primary outcome measure were proportion of no recurrent attack within 52 weeks. Analysis was by intention-to-treat. Results The characteristics of each group at baseline were not significantly different. There was no significant difference in the proportion of no recurrent attack within 52 weeks between the US strategy (87.6%) and ULT strategy (83.4%) groups. There was no significant difference in the occurrence of adverse events (AEs) between the US strategy and ULT strategy groups. Conclusions In chronic gout, if the patients were treated by febuxostat, US without blood examination might be equivalent to uric acid in blood. References A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Chowalloor PV, et al. Ann Rheum Dis. 2013 Jan 3. [Epub ahead of print]2. EULAR evidence based recommendations for gout. Part II:Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Zhang W, et al. Ann Rheum Dis. 2006 Oct;65(10):1312-24. Epub 2006 May 17.3. Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis. Ye P, et al. Clin Ther. 2013 Jan 15. doi:pii: S0149-2918(12)00723-0. 10.1016/j.clinthera.2012.12.011. Disclosure of Interest: None Declared
Url:
DOI: 10.1136/annrheumdis-2013-eular.2955
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001066
- to stream Istex, to step Curation: 000C32
- to stream Istex, to step Checkpoint: 000034
- to stream Main, to step Merge: 000171
- to stream Main, to step Curation: 000169
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">AB0633 Treating to target ultrasound findings only is equivalent to urate-lowering therapy in patients with chronic gout.</title><author><name sortKey="Kume, K" sort="Kume, K" uniqKey="Kume K" first="K." last="Kume">K. Kume</name></author><author><name sortKey="Amano, K" sort="Amano, K" uniqKey="Amano K" first="K." last="Amano">K. Amano</name></author><author><name sortKey="Yamada, S" sort="Yamada, S" uniqKey="Yamada S" first="S." last="Yamada">S. Yamada</name></author><author><name sortKey="Kanazawa, T" sort="Kanazawa, T" uniqKey="Kanazawa T" first="T." last="Kanazawa">T. Kanazawa</name></author><author><name sortKey="Ohta, H" sort="Ohta, H" uniqKey="Ohta H" first="H." last="Ohta">H. Ohta</name></author><author><name sortKey="Hatta, K" sort="Hatta, K" uniqKey="Hatta K" first="K." last="Hatta">K. Hatta</name></author><author><name sortKey="Komori, H" sort="Komori, H" uniqKey="Komori H" first="H." last="Komori">H. Komori</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FE1BBEE8498F41E17D3110517B9A75485AFC8462</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2013-eular.2955</idno><idno type="url">https://api.istex.fr/document/FE1BBEE8498F41E17D3110517B9A75485AFC8462/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001066</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001066</idno><idno type="wicri:Area/Istex/Curation">000C32</idno><idno type="wicri:Area/Istex/Checkpoint">000034</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000034</idno><idno type="wicri:doubleKey">0003-4967:2013:Kume K:ab:treating:to</idno><idno type="wicri:Area/Main/Merge">000171</idno><idno type="wicri:Area/Main/Curation">000169</idno><idno type="wicri:Area/Main/Exploration">000169</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">AB0633 Treating to target ultrasound findings only is equivalent to urate-lowering therapy in patients with chronic gout.</title><author><name sortKey="Kume, K" sort="Kume, K" uniqKey="Kume K" first="K." last="Kume">K. Kume</name><affiliation><wicri:noCountry code="subField">hiroshima</wicri:noCountry></affiliation></author><author><name sortKey="Amano, K" sort="Amano, K" uniqKey="Amano K" first="K." last="Amano">K. Amano</name><affiliation><wicri:noCountry code="subField">hiroshima</wicri:noCountry></affiliation></author><author><name sortKey="Yamada, S" sort="Yamada, S" uniqKey="Yamada S" first="S." last="Yamada">S. Yamada</name><affiliation><wicri:noCountry code="subField">hiroshima</wicri:noCountry></affiliation></author><author><name sortKey="Kanazawa, T" sort="Kanazawa, T" uniqKey="Kanazawa T" first="T." last="Kanazawa">T. Kanazawa</name><affiliation><wicri:noCountry code="subField">hiroshima</wicri:noCountry></affiliation></author><author><name sortKey="Ohta, H" sort="Ohta, H" uniqKey="Ohta H" first="H." last="Ohta">H. Ohta</name><affiliation><wicri:noCountry code="subField">hiroshima</wicri:noCountry></affiliation></author><author><name sortKey="Hatta, K" sort="Hatta, K" uniqKey="Hatta K" first="K." last="Hatta">K. Hatta</name><affiliation></affiliation><affiliation><wicri:noCountry code="subField">Kure</wicri:noCountry></affiliation></author><author><name sortKey="Komori, H" sort="Komori, H" uniqKey="Komori H" first="H." last="Komori">H. Komori</name><affiliation wicri:level="1"><country xml:lang="fr">Japon</country><wicri:regionArea>internal medicine, HIROSHIMA CLINIC, hiroshima</wicri:regionArea><wicri:noRegion>hiroshima</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">Suppl 3</biblScope><biblScope unit="page" from="A982">A982</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">FE1BBEE8498F41E17D3110517B9A75485AFC8462</idno><idno type="DOI">10.1136/annrheumdis-2013-eular.2955</idno><idno type="href">annrheumdis-72-A982-4.pdf</idno><idno type="ArticleID">annrheumdis-2013-eular.2955</idno><idno type="local">annrheumdis;72/Suppl_3/A982-d</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Background Urate-lowering therapy (uric acid<6.0 mg/dL) (ULT) is recommended in chronic gout. In these days ultrasound (US) is very improved, and useful for diagnosis and treatment. Objectives To comparerecurrent gout attacks in chronic gout treated by US findings normalization strategy or ULT strategy. Methods We designed an open label, randomized controlled trial. We screened 74 chronic gout (uric acid>7.0 mg /ld., and double contour sign of US findings in any joint) for inclusion. 63 gout patients were randomly allocated either US strategy group (US group) or ULT group(C group). In both strategies febuxostat is used. US strategy is performed US by 4 weeks. Double contour sign or urate crystals were evaluated; febuxostat is intensified to dissolve it. ULT strategy is performed blood examination by 4 weeks. Febuxostat is intensified to target uric acid <6.0mg/dL. Primary outcome measure were proportion of no recurrent attack within 52 weeks. Analysis was by intention-to-treat. Results The characteristics of each group at baseline were not significantly different. There was no significant difference in the proportion of no recurrent attack within 52 weeks between the US strategy (87.6%) and ULT strategy (83.4%) groups. There was no significant difference in the occurrence of adverse events (AEs) between the US strategy and ULT strategy groups. Conclusions In chronic gout, if the patients were treated by febuxostat, US without blood examination might be equivalent to uric acid in blood. References A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Chowalloor PV, et al. Ann Rheum Dis. 2013 Jan 3. [Epub ahead of print]2. EULAR evidence based recommendations for gout. Part II:Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT). Zhang W, et al. Ann Rheum Dis. 2006 Oct;65(10):1312-24. Epub 2006 May 17.3. Efficacy and Tolerability of Febuxostat in Hyperuricemic Patients With or Without Gout: A Systematic Review and Meta-Analysis. Ye P, et al. Clin Ther. 2013 Jan 15. doi:pii: S0149-2918(12)00723-0. 10.1016/j.clinthera.2012.12.011. Disclosure of Interest: None Declared</div></front></TEI><affiliations><list><country><li>Japon</li></country></list><tree><noCountry><name sortKey="Amano, K" sort="Amano, K" uniqKey="Amano K" first="K." last="Amano">K. Amano</name><name sortKey="Hatta, K" sort="Hatta, K" uniqKey="Hatta K" first="K." last="Hatta">K. Hatta</name><name sortKey="Kanazawa, T" sort="Kanazawa, T" uniqKey="Kanazawa T" first="T." last="Kanazawa">T. Kanazawa</name><name sortKey="Kume, K" sort="Kume, K" uniqKey="Kume K" first="K." last="Kume">K. Kume</name><name sortKey="Ohta, H" sort="Ohta, H" uniqKey="Ohta H" first="H." last="Ohta">H. Ohta</name><name sortKey="Yamada, S" sort="Yamada, S" uniqKey="Yamada S" first="S." last="Yamada">S. Yamada</name></noCountry><country name="Japon"><noRegion><name sortKey="Komori, H" sort="Komori, H" uniqKey="Komori H" first="H." last="Komori">H. Komori</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/NickelMaghrebV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000169 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000169 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= NickelMaghrebV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FE1BBEE8498F41E17D3110517B9A75485AFC8462
|texte= AB0633 Treating to target ultrasound findings only is equivalent to urate-lowering therapy in patients with chronic gout.
}}
| This area was generated with Dilib version V0.6.27. |  |